<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aortic valve sclerosis and pathogenesis of calcific aortic stenosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aortic valve sclerosis and pathogenesis of calcific aortic stenosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Aortic valve sclerosis and pathogenesis of calcific aortic stenosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc Dweck, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine M Otto, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia A Pellikka, MD, FACC, FAHA, FASE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Aortic valve thickening (sclerosis) without stenosis is common in older adults [<a href="#rid1">1</a>]. It is often detected either as a systolic murmur on physical examination or on echocardiography or computed tomography (CT) performed for some other reason. Aortic valve sclerosis is important clinically because it can progress to aortic stenosis and is associated with increased cardiovascular risk.</p><p>This topic will discuss the pathogenesis of aortic sclerosis and calcific aortic stenosis and the diagnosis, prevalence, clinical significance, and management of aortic sclerosis. The natural history, diagnosis, and management of aortic stenosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/8165.html" rel="external">"Natural history, epidemiology, and prognosis of aortic stenosis"</a> and  <a class="medical medical_review" href="/d/html/8164.html" rel="external">"Clinical manifestations and diagnosis of aortic stenosis in adults"</a> and  <a class="medical medical_review" href="/d/html/8130.html" rel="external">"Medical management of symptomatic aortic stenosis"</a> and  <a class="medical medical_review" href="/d/html/8117.html" rel="external">"Medical management of asymptomatic aortic stenosis in adults"</a> and  <a class="medical medical_review" href="/d/html/8154.html" rel="external">"Indications for valve replacement for high gradient aortic stenosis in adults"</a>.)</p><p class="headingAnchor" id="H959465506"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>The prevalence of aortic valve sclerosis in adults increases with age, with rates &lt;10 percent in most study populations with mean age less than 60 years [<a href="#rid2">2</a>]. As an example, in the Monica-KORA study of 935 European adults aged 35 to 84 years, the prevalence of aortic sclerosis increased across the age distribution from 7 percent in those ages 35 to 44 years to 65 percent in those ages 75 to 84 years [<a href="#rid3">3</a>]. Sclerosis of the aortic valve is found in around one quarter of individuals ≥65 years of age [<a href="#rid1">1,4-6</a>], although the rate may be higher in selected individuals of the same age such as those presenting to the emergency department with chest pain [<a href="#rid7">7</a>]. The prevalence is even higher with more advanced age: for example, 35 percent between 75 and 84 years of age and around 50 percent of those over age 80 [<a href="#rid5">5,8</a>].</p><p>Valvular sclerosis is more common in patients with hypertension and electrocardiographic evidence of left ventricular hypertrophy [<a href="#rid9">9</a>] and in those with end-stage kidney disease on maintenance dialysis. Among dialysis patients, aortic and mitral valve sclerosis have been noted in 55 to 69 percent and 40 to 60 percent, respectively [<a href="#rid10">10,11</a>]. However, when adjusted for other cardiovascular risk factors, moderate chronic kidney disease is not significantly associated with aortic valve calcification, although it is associated with mitral annular calcification [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/1909.html" rel="external">"Valvular heart disease in patients with end-stage kidney disease", section on 'Valvular thickening'</a> and  <a class="medical medical_review" href="/d/html/1909.html" rel="external">"Valvular heart disease in patients with end-stage kidney disease", section on 'Valvular and annular calcification'</a>.)</p><p class="headingAnchor" id="H1785456712"><span class="h1">PATHOGENESIS OF CALCIFIC AORTIC VALVE DISEASE</span><span class="headingEndMark"> — </span>The pathobiology of aortic sclerosis and early calcific aortic valve disease shares similarities with atherosclerosis involving lipid accumulation, inflammation, and calcification. Calcification predominates in more advanced stages of aortic stenosis driving valve stiffness and narrowing. The pathobiology of calcific aortic valve disease is an area of active research, and our understanding of the cellular and molecular mechanisms of disease is in flux [<a href="#rid13">13-16</a>].</p><p>It is useful to consider it in two stages: the early initiation phase associated with aortic sclerosis and the later propagation phase associated with more advanced aortic stenosis [<a href="#rid17">17</a>]. The early initiation phase is characterized by three primary processes: lipid accumulation, inflammation, and calcification [<a href="#rid1">1,18,19</a>], and demonstrates similarities to atherosclerosis. Indeed, the incidence of aortic stenosis is related to many of the same risk factors associated with atherosclerosis. By contrast, in the later stages of aortic stenosis (the propagation phase), clear differences with the pathology of atherosclerosis emerge, most notably the predominance of calcification within the leaflets as the key driver to progressive valve stiffness and narrowing.</p><p class="headingAnchor" id="H3699023087"><span class="h2">Initiation phase</span><span class="headingEndMark"> — </span>The early phase of the disease, observed in patients with aortic sclerosis, is characterized by the following pathological findings:</p><p class="bulletIndent1"><span class="glyph">●</span>Focal areas of accumulation of apolipoproteins B, (a), and E, consistent with accumulation of low density lipoprotein (LDL) and lipoprotein(a), also referred to as Lp(a), with evidence of lipoprotein oxidation [<a href="#rid18">18,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammation as evidenced by macrophage and T lymphocyte infiltration on histology [<a href="#rid21">21,22</a>], inflammatory mediators such as interleukin-1-beta and transforming growth factor beta-1 [<a href="#rid23">23,24</a>], and increased 18F-fluorodeoxyglucose uptake on positron emission tomography (PET) scanning [<a href="#rid25">25,26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Local production of proteins that promote tissue calcification, suggesting that valve calcification is actively regulated rather than being an unregulated degenerative process [<a href="#rid27">27-31</a>]. Increased 18F-fluoride activity on PET is a marker of calcification activity [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Production and activity of angiotensin converting enzyme [<a href="#rid33">33,34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upregulation of adhesion molecules and alterations in matrix metalloproteinase activity [<a href="#rid35">35,36</a>].</p><p></p><p class="headingAnchor" id="H4062728397"><span class="h3">Role of mechanical stress</span><span class="headingEndMark"> — </span>Mechanical stress causing endothelial damage is thought to be the precipitating event in the development of aortic sclerosis leading to inflammatory cell infiltration and lipid deposition analogous to that seen in early atherosclerosis [<a href="#rid5">5</a>]. This is perhaps best illustrated by the bicuspid aortic valve, which is associated with increased mechanical stresses in the valve leaflets and the almost invariable development of accelerated valve calcification and stenosis, although these patients may also have a genetic predisposition to tissue calcification [<a href="#rid37">37</a>]. Similarly, it has been speculated that hypertension and the increased stiffness of the aortic root that occurs with ageing may also cause abnormally high mechanical stresses in the valve, in part explaining the association of these two factors with aortic stenosis [<a href="#rid38">38</a>].</p><p>In a cohort study of 5.4 million patients in the United Kingdom with no known cardiovascular disease at baseline, systolic blood pressure was continuously related to the risk of aortic stenosis, with each 20 mmHg increment in systolic blood pressure associated with a 41 percent higher risk of aortic stenosis (hazard ratio 1.41, 95% CI 1.38-1.45). These findings support the concept that mechanical stress is related to development of calcific aortic valve disease [<a href="#rid39">39</a>].</p><p>The association between blood pressure and incidence aortic stenosis was further explored in a Mendelian randomization study. In this study of over 300,000 patients with genetic and blood pressure data, each genetically associated 20 mmHg increment in systolic blood pressure was associated with an increased risk of aortic stenosis (odds ratio [OR] 3.26, 95% CI 1.50-7.10), supporting the causality of hypertension in development of calcific valve disease [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H3619556981"><span class="h3">Relation to atherosclerosis</span><span class="headingEndMark"> — </span>The incidence of aortic sclerosis and stenosis is associated with many of the traditional risk factors for atherosclerosis, supporting pathological similarities between the early stages of these diseases. These include smoking, hypertension, hyperlipidemia, elevated Lp(a) levels, diabetes, and metabolic syndrome [<a href="#rid3">3,5,9,41-48</a>].</p><p>The following echocardiographic studies illustrate the range of associations between the incidence of aortic valve sclerosis, aortic stenosis, and atherosclerotic risk factors:</p><p class="bulletIndent1"><span class="glyph">●</span>A report from the Cardiovascular Health Study (CHS) evaluated 5176 patients ≥65 years of age: 26 percent had aortic valve sclerosis with visually apparent leaflet thickening and/or calcification, and 2 percent had aortic stenosis [<a href="#rid5">5</a>]. Multivariate analysis found significant correlations of aortic valve disease with age, male sex, Lp(a), LDL cholesterol, hypertension, and smoking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Framingham Heart Study offspring cohort (n = 2683, mean age 61 years), 8 percent had at least one calcified valve, 5 percent had aortic sclerosis, and 1 percent had aortic stenosis [<a href="#rid46">46</a>]. The threshold for diagnosis of aortic sclerosis was higher in this study than in the CHS study, and the population was younger, which could explain at least in part the lower rate of aortic sclerosis. Valvular calcification was associated with age, hypertension, and diabetes.</p><p></p><p>Similar findings have been noted when aortic valve calcification was assessed by CT:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Multi-Ethnic Study of Atherosclerosis (MESA) study (n = 6780, mean age 63 years), the prevalence of aortic valve calcification was higher among those with metabolic syndrome (12 percent in women, 22 percent in men) or diabetes (17 percent in women, 24 percent in men) compared with those with neither risk factor (8 percent in women, 14 percent in men) [<a href="#rid47">47</a>]. Metabolic syndrome and diabetes also were associated with a larger number of new cases of aortic valve calcification (OR 1.67, 95% CI 1.21-2.31 for metabolic syndrome and OR 2.06, 95% CI 1.39-3.06 for diabetes) [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast to the CHS study, in a MESA cohort of 5801 non-statin using participants, LDL cholesterol (LDL-C) levels were associated with the presence of aortic valve calcification only in participants younger than 65 years, although the total cholesterol to high density lipoprotein ratio was associated with a slight increase in risk for calcific disease across all ages [<a href="#rid50">50</a>]. There was a significant association between Lp(a) and the degree of aortic valve calcification across a sample of 4678 participants [<a href="#rid51">51</a>]. An Lp(a) &gt;30 mg/dL was significantly associated with aortic valve calcification in White subjects (relative risk [RR] 1.56, 95% CI 1.24-1.96) and was borderline significant in Black participants (RR 1.55, 95% CI 0.98-2.44; p = 0.059). In Hispanic and Chinese participants, no significant associations were observed. An interaction test identified a significant effect of race/ethnicity on the association between Lp(a) and aortic valve calcification.</p><p></p><p>A subsequent study demonstrated that Lp(a) levels &gt;30 mg/dL were associated with increased calcification activity (18F-sodium fluoride on PET), faster disease progression on CT and echocardiography, and increased risk of aortic valve replacement [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H270202220"><span class="h3">Relation to mineral metabolism</span><span class="headingEndMark"> — </span>Disturbances of mineral metabolism may also contribute to the development of aortic valve sclerosis and mitral annular calcification, as suggested by the following observations. In the Cardiovascular Health Study community-based cohort of older adults, each 0.5 mg/dL higher serum phosphate concentration was associated with 17, 12, and 12 percent higher adjusted prevalences of aortic sclerosis, mitral annular calcification, and aortic annular calcification, respectively [<a href="#rid53">53</a>]. Other markers of mineral metabolism, including serum calcium, parathyroid hormone (PTH), and 25 hydroxyvitamin D concentrations, were not associated with either aortic or mitral calcification. Similarly, among participants with chronic kidney disease in MESA, each 1 mg/dL increase in serum phosphate within the normal range (2.5 to 4.5 mg/dL) was associated with 25 and 62 percent higher prevalences of aortic and mitral valve calcification, respectively, after adjustment for traditional risk factors for atherosclerosis, parathyroid hormone, and 1,25 dihydroxyvitamin D levels [<a href="#rid54">54</a>]. However, there are no data to indicate that appropriate calcium supplementation in adults with osteoporosis or osteopenia increases the risk of aortic valve leaflet calcification. (See <a class="local">'Concurrent use of calcium supplements'</a> below.)</p><p class="headingAnchor" id="H1264339726"><span class="h3">Genetic factors</span><span class="headingEndMark"> — </span>Genetic factors contribute to the risk of aortic sclerosis and aortic stenosis [<a href="#rid55">55-65</a>]. Genetic contributions to calcific aortic valve disease were suggested by studies of community-based populations including the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium (this amalgamated participants in the Framingham Heart Study [FHS], MESA, and the Age, Gene/Environment Susceptibility-Reykjavik Study [AGES-RS]) [<a href="#rid62">62,63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A genome-wide association study in 6942 CHARGE participants identified a single-nucleotide polymorphism located in an intron of the Lp(a) gene (rs10455872) that was significantly associated with the presence of aortic valve calcification (OR per allele, 2.05) [<a href="#rid62">62</a>]. The association was confirmed in three additional cohorts of diverse ancestry. The same polymorphism was associated with circulating Lp(a) levels, and with the development of aortic stenosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A Mendelian randomization study found an association between the weighted genetic risk score (GRS, a measure of the genetic predisposition to elevations in plasma lipids) for LDL-C and aortic valve calcium in 6942 participants in the CHARGE consortium [<a href="#rid63">63</a>]. The LDL-C GRS was also associated with incident aortic stenosis identified by national register in the Malmo Diet and Cancer Study (MDCS) population-based cohort.</p><p></p><p>Other risk factors for calcific aortic valve disease include specific polymorphisms in the genes for apolipoprotein E, interleukin-10, the vitamin D receptor, and angiotensin-converting enzyme [<a href="#rid58">58-61</a>]. Patients with familial hypercholesterolemia are at risk for developing severe premature calcific valvular aortic stenosis as well as supravalvular aortic stenosis and premature atherosclerosis [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"</a>.)</p><p>Mutations in the signaling and transcriptional regulator NOTCH1 are associated with a variety of aortic valve anomalies (such as bicuspid aortic valve with or without thoracic aortic aneurysm) and with severe aortic valve calcification in human pedigrees in a nonsyndromic autosomal dominant pattern [<a href="#rid55">55,56</a>]. NOTCH1 transcripts are abundant in the developing aortic valve in mice and may promote valve calcification by diminishing the activity of Runx2, an important transcriptional regulator of the fate of osteoblast cells. This observation is consistent with the suggestion that aortic valve calcification is an active process mediated by the differentiation of valvular cells into osteoblast-like cells [<a href="#rid29">29,55</a>].</p><p>A familial aggregation of calcific aortic stenosis with apparent autosomal dominant inheritance was noted in a report from western France [<a href="#rid57">57</a>]. This aggregation could not be explained by hypercholesterolemia or chronic kidney disease, but a specific genetic abnormality has not yet been identified. A subsequent transcriptome-wide association study in 1009 cases and 1017 ethnically matched controls revealed palmdelphin (PALMD) on chromosome 1p21.2 as significantly associated with calcific aortic valve stenosis. This was replicated in 1391 cases and 352,195 controls from the UK Biobank and also in a large-scale eQTL mapping study of aortic valve tissue where increased disease severity was associated with decreased valve PALMD mRNA expression [<a href="#rid67">67</a>]. The exact function of PALMD in the valve is not known but may have a role in valve interstitial cell differentiation.</p><p class="headingAnchor" id="H3944944723"><span class="h2">Propagation phase</span><span class="headingEndMark"> — </span>The risk factors associated with disease progression in the later stages of aortic stenosis are somewhat different from those governing its incidence. Indeed, the two strongest predictors of disease progression appear to be the severity of aortic stenosis and markers of valve calcification. This suggests pathological differences between the initiation and propagation phases with calcification dominating in the latter and driving progressive valve narrowing [<a href="#rid1">1,18</a>]. The accumulation of valve calcification appears related to the action of osteoblast-like cells and a range of pro-calcific mediators commonly associated with skeletal bone formation. Indeed, a histopathological study of 256 end-stage-excised calcified aortic valves demonstrated widespread evidence of active cartilage and bone formation, with 83 percent of valves showing regions of heterotopic ossification [<a href="#rid30">30</a>]. A PET imaging study in 121 adults with a range of calcific aortic valve severity demonstrated inflammation in early disease. However in patients with moderate and severe aortic stenosis, calcification activity was the dominant observed process [<a href="#rid32">32,68</a>] and closely predicted future disease progression [<a href="#rid69">69,70</a>]. Similarly, assessments of valvular calcium burden provided by both echocardiography and CT also offer powerful prediction of disease progression and clinical events in aortic stenosis [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Aortic sclerosis is an asymptomatic condition that is generally detected either as a systolic ejection murmur on physical examination or as an incidental finding on echocardiography or CT. Aortic sclerosis, in the absence of stenosis, may be associated with a midsystolic ejection murmur, which is usually best heard over the right second interspace. In general, the murmur is brief and not very loud. Importantly, many patients with aortic sclerosis have no murmur on physical examination.</p><p>A normal carotid pulse and normal S2 suggest the absence of aortic stenosis  (<a class="graphic graphic_figure graphicRef61744" href="/d/graphic/61744.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults"</a>.)</p><p>However, the physical examination is neither sensitive nor specific for excluding aortic valve obstruction. Thus, echocardiography should be performed to distinguish aortic sclerosis from aortic stenosis and other cardiac abnormalities that might account for the murmur when present.</p><p class="headingAnchor" id="H2649921"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Aortic sclerosis should be suspected when a systolic murmur is heard on auscultation but is also frequently detected as an incidental finding on transthoracic echocardiography or as aortic valve calcification or thickening on CT.</p><p>Aortic sclerosis is defined on echocardiography as irregular aortic leaflet thickening and focal increased echogenicity without impairment of leaflet excursion and with peak Doppler velocities across the valve &lt;2 m/s. On CT, aortic sclerosis can be defined by the presence of leaflet thickening or the presence of calcific deposits within the aortic valve leaflets.</p><p>Aortic valve sclerosis is defined by the following features on echocardiography [<a href="#rid1">1,4,5,72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Irregular leaflet thickening and focal increased echogenicity (calcification) are the hallmarks of the condition. Focal areas of thickening are typically seen on the aortic side of the valve in the center of the valve cusp, rather than at the leaflet edges, often initially involving the noncoronary cusp.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leaflet excursion is not impaired and the commissures are not fused. Peak continuous wave Doppler flow velocities across the valve are normal or only minimally elevated (&lt;2 m/sec).</p><p></p><p>Mitral annular calcification frequently accompanies aortic valve sclerosis [<a href="#rid73">73,74</a>]. (See  <a class="medical medical_review" href="/d/html/5334.html" rel="external">"Echocardiographic evaluation of the mitral valve", section on 'Mitral annular calcification'</a> and  <a class="medical medical_review" href="/d/html/8122.html" rel="external">"Clinical manifestations and diagnosis of mitral annular calcification"</a>.)</p><p>Reduction in leaflet mobility, increases in leaflet calcification, and increases in aortic transvalvular Doppler flow velocities are signs of progression from aortic sclerosis to aortic stenosis  (<a class="graphic graphic_table graphicRef95224" href="/d/graphic/95224.html" rel="external">table 1</a>). (See <a class="local">'Progression to aortic stenosis'</a> below.)</p><p class="headingAnchor" id="H2175526648"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Aortic sclerosis should be differentiated from other causes of a systolic murmur, including the following conditions based on clinical signs  (<a class="graphic graphic_figure graphicRef61744" href="/d/graphic/61744.html" rel="external">figure 1</a>), electrocardiogram, and echocardiogram. As noted above, aortic sclerosis may or may not be associated with a midsystolic ejection murmur. However, differentiation of murmurs of these various conditions on physical examination is challenging and even experts cannot reliably distinguish these conditions by exam alone. Echocardiography is recommended when valve disease is suspected [<a href="#rid75">75,76</a>], including in asymptomatic adults with a grade 3 or louder murmur and in adults with potential cardiac symptoms and any cardiac murmur. (See  <a class="medical medical_review" href="/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Aortic stenosis is associated with a midsystolic ejection murmur that radiates into the neck and over both carotid arteries  (<a class="graphic graphic_table graphicRef51024" href="/d/graphic/51024.html" rel="external">table 2</a>). Aortic stenosis is associated with evidence of flow obstruction in addition to valve thickening on echocardiography. (See  <a class="medical medical_review" href="/d/html/8164.html" rel="external">"Clinical manifestations and diagnosis of aortic stenosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supravalvular aortic stenosis is associated with a midsystolic ejection murmur. Echocardiography is helpful in identifying the location of obstruction above the aortic valve. (See  <a class="medical medical_review" href="/d/html/5775.html" rel="external">"Valvar aortic stenosis in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subvalvular aortic stenosis is associated with a midsystolic ejection murmur. Echocardiography is helpful in identifying the location and structure of the subaortic lesion. (See  <a class="medical medical_review" href="/d/html/5776.html" rel="external">"Subvalvar aortic stenosis (subaortic stenosis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mitral regurgitation (MR) is generally associated with a holosystolic murmur. Echocardiographic findings include mitral valve apparatus abnormalities consistent with primary or secondary MR as well as Doppler findings that aid in identifying and quantifying the MR jet. (See  <a class="medical medical_review" href="/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertrophic cardiomyopathy with dynamic outflow obstruction causes a midsystolic ejection murmur that increases upon standing from a squatting position. Echocardiographic findings include unexplained left ventricular hypertrophy, systolic anterior motion of the mitral valve, as well as Doppler evidence of left ventricular outflow obstruction. (See  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Echocardiography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ventricular septal defects (VSDs) typically cause a holosystolic murmur if right ventricular pressure is lower than left ventricular pressure throughout systole. An echocardiogram is a sensitive means of detecting most VSDs. (See  <a class="medical medical_review" href="/d/html/13602.html" rel="external">"Clinical manifestations and diagnosis of ventricular septal defect in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An innocent midsystolic flow murmur is commonly thought to originate from vibrations in the pulmonary trunk. When an innocent murmur is present, an echocardiogram reveals no underlying cardiac lesion. (See  <a class="medical medical_review" href="/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults", section on 'Innocent midsystolic murmurs'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL SIGNIFICANCE OF AORTIC SCLEROSIS</span><span class="headingEndMark"> — </span>Aortic valve sclerosis can progress to aortic stenosis and is a marker for increased cardiovascular risk.</p><p class="headingAnchor" id="H9"><span class="h2">Progression to aortic stenosis</span><span class="headingEndMark"> — </span>As aortic valve leaflet thickening and calcification progress, the increased valve stiffness results in obstruction at the valve level and transition from aortic sclerosis to stenosis [<a href="#rid4">4</a>]. Prospective clinical studies suggest that this progression occurs in approximately one of eight patients, with progression from sclerosis to severe stenosis occurring in 1 out of 64 patients [<a href="#rid74">74,77</a>]. In a meta-analysis of 22 studies, the rate of progression from aortic sclerosis to aortic stenosis was 1.8 to 1.9 percent per year [<a href="#rid2">2</a>]. These low conversion rates put into question the rationale of strategies aimed at treating aortic sclerosis in order to prevent the development of aortic stenosis. (See  <a class="medical medical_review" href="/d/html/8165.html" rel="external">"Natural history, epidemiology, and prognosis of aortic stenosis"</a>.)</p><p>Unlike atherosclerosis, in which clinical events are due to plaque rupture and thrombosis, obstruction in calcific aortic stenosis is due to the bulk of the lesion rather than plaque instability. It is likely that the disease process is accelerated by abnormal shear or mechanical stress on the leaflet. This could explain why symptomatic calcification in patients with bicuspid aortic valves occurs about 10 years earlier than in patients with trileaflet valves. In most patients, a bicuspid aortic valve functions normally for many years. A subset of patients develop significant regurgitation, but most are asymptomatic until superimposed calcification results in obstruction to flow later in life. (See  <a class="medical medical_review" href="/d/html/8157.html" rel="external">"Clinical manifestations and diagnosis of bicuspid aortic valve in adults"</a>.)</p><p>The likelihood of progression was assessed in a review of 2131 patients with aortic valve thickening detected on echocardiography: aortic stenosis developed in 338 (16 percent) after seven years [<a href="#rid74">74</a>]. The stenosis was mild to moderate in 84 percent and severe in 16 percent. Only mitral annular calcification, a pathologic process similar to aortic valve sclerosis, was significantly associated with progression in multivariable analysis. As described in the next section, both aortic valve sclerosis and mitral annular calcification may also be predictors of cardiovascular events and mortality. A similar rate of progression to aortic stenosis was observed in the Cardiovascular Health Study cohort in which 9 percent of subjects with aortic sclerosis progressed to aortic stenosis in five years [<a href="#rid78">78</a>].</p><p>Factors associated with progressive aortic valve calcification were identified in 5880 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) [<a href="#rid79">79</a>]. The incidence rate of aortic valve calcium was 1.7 percent per year. Risk factors for incident aortic valve calcium included older age, male sex, a higher body mass index, current smoking, and the use of lipid-lowering and antihypertensive medications. The risk of aortic valve calcium progression was associated with male sex and, consistent with other studies, the severity of baseline calcification.</p><p class="headingAnchor" id="H10"><span class="h2">Predictor of cardiovascular events and mortality</span><span class="headingEndMark"> — </span>Aortic sclerosis is consistently associated with an increased risk of cardiovascular events [<a href="#rid2">2</a>].</p><p>This was illustrated by a meta-analysis of 22 studies that reported that subjects with aortic sclerosis had a 68 percent increased risk of coronary events, 27 percent increased risk of stroke, 69 percent increased risk of cardiovascular mortality, and 36 percent increased risk of all-cause mortality compared with subjects without this condition [<a href="#rid2">2</a>].</p><p>The mechanisms responsible for the association between aortic valve sclerosis and cardiovascular events and mortality are not fully understood [<a href="#rid1">1,80</a>]. The valve lesion itself is not likely to be important, since hemodynamics are normal or near normal and the time to increased risk is short compared with the possible rate of progression to aortic stenosis (see <a class="local">'Pathogenesis of calcific aortic valve disease'</a> above). A more probable explanation is that, given the common risk factors (see <a class="local">'Relation to atherosclerosis'</a> above), aortic valve sclerosis is a marker for underlying atherosclerosis [<a href="#rid7">7,80</a>]. An analysis of the SCOTHEART trial, in which CT was performed in outpatients with chest pain, found that patients with aortic or mitral valve calcification had higher coronary calcium scores and more obstructive coronary artery disease. It also again confirmed the association between both aortic valve and mitral annular calcification and adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke). However, these associations were lost when coronary CT calcium scores or obstructive coronary artery disease were considered in the model. This would suggest the association between aortic sclerosis and atherothrombotic events is noncausal and instead mediated by associated atheroma [<a href="#rid81">81</a>]. This suggests that the finding of aortic sclerosis or mitral annular calcification on echocardiography is a marker of increased risk of coronary disease. However, data are lacking on whether this finding should prompt further diagnostic evaluation or a change in cardiovascular preventive therapies.</p><p class="headingAnchor" id="H11"><span class="h2">Embolic risk</span><span class="headingEndMark"> — </span>Although calcific microemboli have been observed in patients with calcific aortic valve disease, these appear to be rarely associated with clinical events [<a href="#rid82">82</a>]. No significant increase in stroke risk was found in studies comparing patients with aortic stenosis or aortic sclerosis with matched controls [<a href="#rid4">4,83,84</a>].</p><p class="headingAnchor" id="H12"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Patients with aortic sclerosis should receive follow-up for progression to aortic stenosis and full assessment of their cardiovascular risk profile with lifestyle and risk factor modification as appropriate [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H2654431"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>Aortic valve sclerosis is a major type of Stage A (meaning "at risk of") valvular aortic stenosis (along with bicuspid aortic valve)  (<a class="graphic graphic_table graphicRef95224" href="/d/graphic/95224.html" rel="external">table 1</a>). Since aortic sclerosis often progresses to aortic stenosis, clinical follow-up by the primary care provider is recommended with periodic (at least annual) evaluation for changes in cardiac symptoms or signs. Follow-up echocardiography is appropriate to evaluate any new cardiac symptoms, such as dyspnea on exertion, or changes in physical examination findings, such as an increase in the loudness of the murmur, a single second heart sound, or a decrease in carotid upstroke. In addition, we favor repeating an echocardiogram every five years in adults with aortic sclerosis, as symptoms do not develop until late in the disease process and may not be appreciated by the patient and changes in physical examination findings may be subtle.</p><p class="headingAnchor" id="H13"><span class="h2">Risk factor modification</span><span class="headingEndMark"> — </span>A prudent approach is to consider aortic valve sclerosis to be a marker of increased cardiovascular risk [<a href="#rid1">1,42</a>]. Thus, all patients with aortic sclerosis should undergo a careful history and physical examination with assessment of conventional cardiac risk factors, including hypertension, smoking, diabetes, and hyperlipidemia. Risk factor reduction should be instituted based upon accepted guidelines. In addition, further diagnostic evaluation may be needed in patients with clinical signs or symptoms of cardiovascular disease. (See  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a> and  <a class="medical medical_review" href="/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a>.)</p><p>Aside from their beneficial effects with respect to atherosclerosis, there are no controlled trials to confirm whether aggressive control of blood pressure or other non-lipid risk factors for coronary heart disease will reduce the progression of aortic valve sclerosis or stenosis. Although histologic evidence of lipid infiltration is seen early in the disease process and small retrospective studies were promising, there is no convincing evidence of benefit from lipid lowering therapy in adults with calcific aortic valve disease. In two prospective randomized trials of statin (hydroxymethylglutaryl CoA [HMG CoA] reductase inhibitor) versus placebo in adults with mild to moderate calcific aortic stenosis, no difference was found in the rate of hemodynamic progression [<a href="#rid86">86,87</a>]. In addition, the larger, prospective, randomized SEAS trial in adults with mild to moderate aortic stenosis found no benefit of aggressive lipid lowering therapy on a combined cardiovascular endpoint [<a href="#rid88">88</a>]. Ongoing randomized controlled trials are assessing whether drugs targeting calcium metabolism more directly may be more effective in slowing aortic stenosis progression. There is also interest in modifying lipoprotein(a) levels as a novel treatment strategy. (See  <a class="medical medical_review" href="/d/html/8117.html" rel="external">"Medical management of asymptomatic aortic stenosis in adults", section on 'Hypercholesterolemia and statin therapy'</a>.)</p><p class="headingAnchor" id="H1606612617"><span class="h2">Concurrent use of calcium supplements</span><span class="headingEndMark"> — </span>For adults with aortic valve leaflet calcification with indications for calcium supplementation, we continue calcium supplements. As noted above, disturbances of mineral metabolism may contribute to the development of aortic valve sclerosis and mitral annular calcification. However, there are no data to indicate that appropriate calcium supplementation in adults with osteoporosis or osteopenia increases the risk of aortic valve leaflet calcification. (See <a class="local">'Relation to mineral metabolism'</a> above and  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.)</p><p class="headingAnchor" id="H2684464968"><span class="h2">Therapies that are not indicated</span></p><p class="headingAnchor" id="H14"><span class="h3">Antithrombotic therapy</span><span class="headingEndMark"> — </span>As noted in the 2012 American College of Chest Physicians guidelines, antithrombotic therapy does not have a role in management of calcific aortic valve disease [<a href="#rid89">89</a>]. Embolic events are not significantly associated with aortic valve sclerosis. No treatment has been established for prevention of calcific microemboli. (See <a class="local">'Embolic risk'</a> above.)</p><p>Patients with calcific aortic valve disease who have had an ischemic stroke or transient ischemic attack (TIA) with no other identifiable source should be managed according to standard guidelines for secondary prevention of noncardioembolic stroke or TIA. (See  <a class="medical medical_review" href="/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke", section on 'Summary and recommendations'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Endocarditis prophylaxis</span><span class="headingEndMark"> — </span>Endocarditis prophylaxis is <strong>not</strong> recommended in patients with aortic valve sclerosis [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p class="headingAnchor" id="H3337096500"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a>.)</p><p class="headingAnchor" id="H12603696"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Aortic sclerosis is an asymptomatic condition that is generally detected either as a systolic ejection murmur on physical examination or as an incidental finding on echocardiography or computed tomography. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of aortic sclerosis increases with age from less than 10 percent in middle-aged adults to ≥25 percent in adults ≥65 years old. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pathobiology of aortic sclerosis and early calcific aortic valve disease (the initiation phase) shares similarities with atherosclerosis involving lipid accumulation, inflammation, and calcification. The incidence of aortic sclerosis has been correlated with clinical risk factors for atherosclerosis, including smoking, hypertension, hyperlipidemia, and diabetes. The factors driving aortic stenosis progression in the propagation phase appear different, with calcification predominating. (See <a class="local">'Pathogenesis of calcific aortic valve disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic factors, including some linked to dyslipidemia, contribute to the risk of aortic valve calcification and development of calcific aortic stenosis. (See <a class="local">'Genetic factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aortic sclerosis is defined as irregular aortic leaflet thickening and focal increased echogenicity without impairment of leaflet excursion and with peak Doppler velocities across the valve &lt;2 m/s. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since aortic sclerosis can progress to aortic stenosis, clinical follow-up is recommended with periodic (eg, at yearly or greater intervals) evaluation for changes in cardiac symptoms or signs. Follow-up echocardiography is appropriate to evaluate any new cardiac symptoms, such as dyspnea on exertion, or changes in physical examination findings, such as an increase in the loudness of the murmur, a single second heart sound, or a decrease in carotid upstroke. In addition, we favor repeating an echocardiogram every five years in adults with aortic sclerosis. (See <a class="local">'Follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with aortic valve sclerosis (including those with and without known cardiovascular disease) have an increased frequency of cardiovascular events and mortality. This may be explained by the association between aortic valve sclerosis and coronary and carotid atherosclerosis rather than representing a direct causal effect. (See <a class="local">'Predictor of cardiovascular events and mortality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with aortic sclerosis should undergo a careful history and physical examination with assessment of conventional cardiac risk factors, including hypertension, smoking, diabetes, and hyperlipidemia. Risk factor reduction should be instituted based upon accepted guidelines. In addition, further diagnostic evaluation may be needed in patients with clinical signs or symptoms of cardiovascular disease. (See <a class="local">'Risk factor modification'</a> above and  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a> and  <a class="medical medical_review" href="/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no convincing evidence of benefit from lipid lowering therapy in adults with calcific aortic valve disease separate from established cardiovascular indications for such therapy. (See <a class="local">'Risk factor modification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no data to indicate that appropriate calcium supplementation in adults with osteoporosis or osteopenia increases the risk of aortic valve leaflet calcification. Because of this, we do not discontinue calcium supplements in adults with aortic valve calcification. (See <a class="local">'Concurrent use of calcium supplements'</a> above.)</p><p></p><p class="headingAnchor" id="H526079231"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David S Siscovick, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111:3316.</a></li><li><a class="nounderline abstract_t">Coffey S, Cox B, Williams MJ. The prevalence, incidence, progression, and risks of aortic valve sclerosis: a systematic review and meta-analysis. J Am Coll Cardiol 2014; 63:2852.</a></li><li><a class="nounderline abstract_t">Stritzke J, Linsel-Nitschke P, Markus MR, et al. Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey. Eur Heart J 2009; 30:2044.</a></li><li><a class="nounderline abstract_t">Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999; 341:142.</a></li><li><a class="nounderline abstract_t">Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29:630.</a></li><li><a class="nounderline abstract_t">Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21:1220.</a></li><li><a class="nounderline abstract_t">Chandra HR, Goldstein JA, Choudhary N, et al. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol 2004; 43:169.</a></li><li><a class="nounderline abstract_t">Aronow WS, Ahn C, Shirani J, Kronzon I. Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis. Am J Cardiol 1999; 83:599.</a></li><li><a class="nounderline abstract_t">Olsen MH, Wachtell K, Bella JN, et al. Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). Am J Cardiol 2005; 95:132.</a></li><li><a class="nounderline abstract_t">Straumann E, Meyer B, Misteli M, et al. Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis. Br Heart J 1992; 67:236.</a></li><li><a class="nounderline abstract_t">Stinebaugh J, Lavie CJ, Milani RV, et al. Doppler echocardiographic assessment of valvular heart disease in patients requiring hemodialysis for end-stage renal disease. South Med J 1995; 88:65.</a></li><li><a class="nounderline abstract_t">Ix JH, Shlipak MG, Katz R, et al. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2007; 50:412.</a></li><li><a class="nounderline abstract_t">O'Brien KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006; 26:1721.</a></li><li><a class="nounderline abstract_t">Bossé Y, Mathieu P, Pibarot P. Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis. J Am Coll Cardiol 2008; 51:1327.</a></li><li><a class="nounderline abstract_t">Pasipoularides A. Calcific Aortic Valve Disease: Part 1--Molecular Pathogenetic Aspects, Hemodynamics, and Adaptive Feedbacks. J Cardiovasc Transl Res 2016; 9:102.</a></li><li><a class="nounderline abstract_t">Aikawa E, Hutcheson JD. The Developmental Origin of Calcific Aortic Stenosis. N Engl J Med 2022; 386:1372.</a></li><li><a class="nounderline abstract_t">Pawade TA, Newby DE, Dweck MR. Calcification in Aortic Stenosis: The Skeleton Key. J Am Coll Cardiol 2015; 66:561.</a></li><li><a class="nounderline abstract_t">Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90:844.</a></li><li><a class="nounderline abstract_t">Rajamannan NM. Calcific aortic valve disease: cellular origins of valve calcification. Arterioscler Thromb Vasc Biol 2011; 31:2777.</a></li><li><a class="nounderline abstract_t">Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999; 19:1218.</a></li><li><a class="nounderline abstract_t">Wallby L, Janerot-Sjöberg B, Steffensen T, Broqvist M. T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 2002; 88:348.</a></li><li><a class="nounderline abstract_t">Olsson M, Rosenqvist M, Nilsson J. Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis. J Am Coll Cardiol 1994; 24:1664.</a></li><li><a class="nounderline abstract_t">Kaden JJ, Dempfle CE, Grobholz R, et al. Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis 2003; 170:205.</a></li><li><a class="nounderline abstract_t">Jian B, Narula N, Li QY, et al. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 2003; 75:457.</a></li><li><a class="nounderline abstract_t">Marincheva-Savcheva G, Subramanian S, Qadir S, et al. Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography increased valvular fluorodeoxyglucose uptake in aortic stenosis. J Am Coll Cardiol 2011; 57:2507.</a></li><li><a class="nounderline abstract_t">Abdelbaky A, Corsini E, Figueroa AL, et al. Early aortic valve inflammation precedes calcification: a longitudinal FDG-PET/CT study. Atherosclerosis 2015; 238:165.</a></li><li><a class="nounderline abstract_t">O'Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995; 92:2163.</a></li><li><a class="nounderline abstract_t">Mohler ER 3rd, Adam LP, McClelland P, et al. Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol 1997; 17:547.</a></li><li><a class="nounderline abstract_t">Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003; 107:2181.</a></li><li><a class="nounderline abstract_t">Mohler ER 3rd, Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. Circulation 2001; 103:1522.</a></li><li><a class="nounderline abstract_t">Kaden JJ, Bickelhaupt S, Grobholz R, et al. Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004; 13:560.</a></li><li><a class="nounderline abstract_t">Dweck MR, Jones C, Joshi NV, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 2012; 125:76.</a></li><li><a class="nounderline abstract_t">O'Brien KD, Shavelle DM, Caulfield MT, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002; 106:2224.</a></li><li><a class="nounderline abstract_t">Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004; 44:1859.</a></li><li><a class="nounderline abstract_t">Ghaisas NK, Foley JB, O'Briain DS, et al. Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. J Am Coll Cardiol 2000; 36:2257.</a></li><li><a class="nounderline abstract_t">Jian B, Jones PL, Li Q, et al. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 2001; 159:321.</a></li><li><a class="nounderline abstract_t">Weinberg EJ, Kaazempur Mofrad MR. A multiscale computational comparison of the bicuspid and tricuspid aortic valves in relation to calcific aortic stenosis. J Biomech 2008; 41:3482.</a></li><li><a class="nounderline abstract_t">Robicsek F, Thubrikar MJ, Fokin AA. Cause of degenerative disease of the trileaflet aortic valve: review of subject and presentation of a new theory. Ann Thorac Surg 2002; 73:1346.</a></li><li><a class="nounderline abstract_t">Rahimi K, Mohseni H, Kiran A, et al. Elevated blood pressure and risk of aortic valve disease: a cohort analysis of 5.4 million UK adults. Eur Heart J 2018; 39:3596.</a></li><li><a class="nounderline abstract_t">Nazarzadeh M, Pinho-Gomes AC, Smith Byrne K, et al. Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study. JAMA Cardiol 2019; 4:788.</a></li><li><a class="nounderline abstract_t">Taylor HA Jr, Clark BL, Garrison RJ, et al. Relation of aortic valve sclerosis to risk of coronary heart disease in African-Americans. Am J Cardiol 2005; 95:401.</a></li><li><a class="nounderline abstract_t">Agmon Y, Khandheria BK, Meissner I, et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol 2001; 38:827.</a></li><li><a class="nounderline abstract_t">Pohle K, Mäffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001; 104:1927.</a></li><li><a class="nounderline abstract_t">Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987; 59:998.</a></li><li><a class="nounderline abstract_t">Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995; 76:928.</a></li><li><a class="nounderline abstract_t">Fox CS, Guo CY, Larson MG, et al. Relations of inflammation and novel risk factors to valvular calcification. Am J Cardiol 2006; 97:1502.</a></li><li><a class="nounderline abstract_t">Katz R, Wong ND, Kronmal R, et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006; 113:2113.</a></li><li><a class="nounderline abstract_t">Briand M, Lemieux I, Dumesnil JG, et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006; 47:2229.</a></li><li><a class="nounderline abstract_t">Katz R, Budoff MJ, Takasu J, et al. Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes 2009; 58:813.</a></li><li><a class="nounderline abstract_t">Owens DS, Katz R, Johnson E, et al. Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Arch Intern Med 2008; 168:1200.</a></li><li><a class="nounderline abstract_t">Cao J, Steffen BT, Budoff M, et al. Lipoprotein(a) Levels Are Associated With Subclinical Calcific Aortic Valve Disease in White and Black Individuals: The Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2016; 36:1003.</a></li><li><a class="nounderline abstract_t">Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. J Am Coll Cardiol 2019; 73:2150.</a></li><li><a class="nounderline abstract_t">Linefsky JP, O'Brien KD, Katz R, et al. Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study. J Am Coll Cardiol 2011; 58:291.</a></li><li><a class="nounderline abstract_t">Adeney KL, Siscovick DS, Ix JH, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20:381.</a></li><li><a class="nounderline abstract_t">Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005; 437:270.</a></li><li><a class="nounderline abstract_t">McKellar SH, Tester DJ, Yagubyan M, et al. Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2007; 134:290.</a></li><li><a class="nounderline abstract_t">Probst V, Le Scouarnec S, Legendre A, et al. Familial aggregation of calcific aortic valve stenosis in the western part of France. Circulation 2006; 113:856.</a></li><li><a class="nounderline abstract_t">Novaro GM, Sachar R, Pearce GL, et al. Association between apolipoprotein E alleles and calcific valvular heart disease. Circulation 2003; 108:1804.</a></li><li><a class="nounderline abstract_t">Ortlepp JR, Schmitz F, Mevissen V, et al. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J 2004; 25:514.</a></li><li><a class="nounderline abstract_t">Ortlepp JR, Hoffmann R, Ohme F, et al. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 2001; 85:635.</a></li><li><a class="nounderline abstract_t">Ertas FS, Hasan T, Ozdol C, et al. Relationship between angiotensin-converting enzyme gene polymorphism and severity of aortic valve calcification. Mayo Clin Proc 2007; 82:944.</a></li><li><a class="nounderline abstract_t">Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368:503.</a></li><li><a class="nounderline abstract_t">Smith JG, Luk K, Schulz CA, et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA 2014; 312:1764.</a></li><li><a class="nounderline abstract_t">Bella JN, Tang W, Kraja A, et al. Genome-wide linkage mapping for valve calcification susceptibility loci in hypertensive sibships: the Hypertension Genetic Epidemiology Network Study. Hypertension 2007; 49:453.</a></li><li><a class="nounderline abstract_t">Smith JG, Newton-Cheh C. Genome-wide association studies of late-onset cardiovascular disease. J Mol Cell Cardiol 2015; 83:131.</a></li><li><a class="nounderline abstract_t">Fantus D, Awan Z, Seidah NG, Genest J. Aortic calcification: Novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor. Atherosclerosis 2013; 226:9.</a></li><li><a class="nounderline abstract_t">Thériault S, Gaudreault N, Lamontagne M, et al. A transcriptome-wide association study identifies PALMD as a susceptibility gene for calcific aortic valve stenosis. Nat Commun 2018; 9:988.</a></li><li><a class="nounderline abstract_t">Aikawa E, Otto CM. Look more closely at the valve: imaging calcific aortic valve disease. Circulation 2012; 125:9.</a></li><li><a class="nounderline abstract_t">Dweck MR, Jenkins WS, Vesey AT, et al. 18F-sodium fluoride uptake is a marker of active calcification and disease progression in patients with aortic stenosis. Circ Cardiovasc Imaging 2014; 7:371.</a></li><li><a class="nounderline abstract_t">Jenkins WS, Vesey AT, Shah AS, et al. Valvular (18)F-Fluoride and (18)F-Fluorodeoxyglucose Uptake Predict Disease Progression and Clinical Outcome in Patients With Aortic Stenosis. J Am Coll Cardiol 2015; 66:1200.</a></li><li><a class="nounderline abstract_t">Clavel MA, Pibarot P, Messika-Zeitoun D, et al. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study. J Am Coll Cardiol 2014; 64:1202.</a></li><li><a class="nounderline abstract_t">Gharacholou SM, Karon BL, Shub C, Pellikka PA. Aortic valve sclerosis and clinical outcomes: moving toward a definition. Am J Med 2011; 124:103.</a></li><li><a class="nounderline abstract_t">Jeon DS, Atar S, Brasch AV, et al. Association of mitral annulus calcification, aortic valve sclerosis and aortic root calcification with abnormal myocardial perfusion single photon emission tomography in subjects age &lt; or =65 years old. J Am Coll Cardiol 2001; 38:1988.</a></li><li><a class="nounderline abstract_t">Faggiano P, Antonini-Canterin F, Erlicher A, et al. Progression of aortic valve sclerosis to aortic stenosis. Am J Cardiol 2003; 91:99.</a></li><li><a class="nounderline abstract_t">Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33:2451.</a></li><li><a class="nounderline abstract_t">Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72.</a></li><li><a class="nounderline abstract_t">Cosmi JE, Kort S, Tunick PA, et al. The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. Arch Intern Med 2002; 162:2345.</a></li><li><a class="nounderline abstract_t">Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol 2007; 50:1992.</a></li><li><a class="nounderline abstract_t">Owens DS, Katz R, Takasu J, et al. Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA). Am J Cardiol 2010; 105:701.</a></li><li><a class="nounderline abstract_t">Otto CM. Why is aortic sclerosis associated with adverse clinical outcomes? J Am Coll Cardiol 2004; 43:176.</a></li><li><a class="nounderline abstract_t">Williams MC, Massera D, Moss AJ, et al. Prevalence and clinical implications of valvular calcification on coronary computed tomography angiography. Eur Heart J Cardiovasc Imaging 2021; 22:262.</a></li><li><a class="nounderline abstract_t">HOLLEY KE, BAHN RC, MCGOON DC, MANKIN HT. SPONTANEOUS CALCIFIC EMBOLIZATION ASSOCIATED WITH CALCIFIC AORTIC STENOSIS. Circulation 1963; 27:197.</a></li><li><a class="nounderline abstract_t">Boon A, Lodder J, Cheriex E, Kessels F. Risk of stroke in a cohort of 815 patients with calcification of the aortic valve with or without stenosis. Stroke 1996; 27:847.</a></li><li><a class="nounderline abstract_t">Kizer JR, Wiebers DO, Whisnant JP, et al. Mitral annular calcification, aortic valve sclerosis, and incident stroke in adults free of clinical cardiovascular disease: the Strong Heart Study. Stroke 2005; 36:2533.</a></li><li><a class="nounderline abstract_t">Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S.</a></li><li><a class="nounderline abstract_t">Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352:2389.</a></li><li><a class="nounderline abstract_t">Chan KL, Teo K, Dumesnil JG, et al. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010; 121:306.</a></li><li><a class="nounderline abstract_t">Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343.</a></li><li><a class="nounderline abstract_t">Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.</a></li></ol></div><div id="topicVersionRevision">Topic 8123 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15967862" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24814496" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The prevalence, incidence, progression, and risks of aortic valve sclerosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608594" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10403851" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060903" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8459080" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14736432" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073870" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15619412" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1554541" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7817230" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Doppler echocardiographic assessment of valvular heart disease in patients requiring hemodialysis for end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17720520" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16709942" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18387432" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26891845" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Calcific Aortic Valve Disease: Part 1--Molecular Pathogenetic Aspects, Hemodynamics, and Adaptive Feedbacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35388675" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Developmental Origin of Calcific Aortic Stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26227196" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Calcification in Aortic Stenosis: The Skeleton Key.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7519131" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22096095" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Calcific aortic valve disease: cellular origins of valve calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10323772" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12231589" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7963113" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14612199" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12607654" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679852" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography increased valvular fluorodeoxyglucose uptake in aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25525744" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Early aortic valve inflammation precedes calcification: a longitudinal FDG-PET/CT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7554197" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Osteopontin is expressed in human aortic valvular lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9102175" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Detection of osteopontin in calcified human aortic valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12719282" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Human aortic valve calcification is associated with an osteoblast phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11257079" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bone formation and inflammation in cardiac valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15311861" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22090163" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390952" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15519020" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Induction of local angiotensin II-producing systems in stenotic aortic valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11127470" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438479" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18996528" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A multiscale computational comparison of the bicuspid and tricuspid aortic valves in relation to calcific aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11996298" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cause of degenerative disease of the trileaflet aortic valve: review of subject and presentation of a new theory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30212891" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Elevated blood pressure and risk of aortic valve disease: a cohort analysis of 5.4 million UK adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31290937" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15670554" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Relation of aortic valve sclerosis to risk of coronary heart disease in African-Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11527641" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602496" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3565291" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7484833" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16679093" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Relations of inflammation and novel risk factors to valvular calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636166" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16750688" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19136658" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression: the Multi-Ethnic Study of Atherosclerosis (MESA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541828" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26941019" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Lipoprotein(a) Levels Are Associated With Subclinical Calcific Aortic Valve Disease in White and Black Individuals: The Multi-Ethnic Study of Atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31047003" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21737022" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19073826" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Association of serum phosphate with vascular and valvular calcification in moderate CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16025100" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mutations in NOTCH1 cause aortic valve disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17662764" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461814" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Familial aggregation of calcific aortic valve stenosis in the western part of France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14530190" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Association between apolipoprotein E alleles and calcific valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15039132" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11359741" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17673063" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Relationship between angiotensin-converting enzyme gene polymorphism and severity of aortic valve calcification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388002" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Genetic associations with valvular calcification and aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25344734" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224468" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Genome-wide linkage mapping for valve calcification susceptibility loci in hypertensive sibships: the Hypertension Genetic Epidemiology Network Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25870159" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Genome-wide association studies of late-onset cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23040868" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Aortic calcification: Novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29511167" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A transcriptome-wide association study identifies PALMD as a susceptibility gene for calcific aortic valve stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22090164" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Look more closely at the valve: imaging calcific aortic valve disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24508669" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : 18F-sodium fluoride uptake is a marker of active calcification and disease progression in patients with aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26338001" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Valvular (18)F-Fluoride and (18)F-Fluorodeoxyglucose Uptake Predict Disease Progression and Clinical Outcome in Patients With Aortic Stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25236511" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21295189" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Aortic valve sclerosis and clinical outcomes: moving toward a definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11738305" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Association of mitral annulus calcification, aortic valve sclerosis and aortic root calcification with abnormal myocardial perfusion single photon emission tomography in subjects age&lt;or =65 years old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12505585" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Progression of aortic valve sclerosis to aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22922415" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Guidelines on the management of valvular heart disease (version 2012).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332150" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12418948" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17996566" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185020" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14736433" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Why is aortic sclerosis associated with adverse clinical outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33306104" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prevalence and clinical implications of valvular calcification on coronary computed tomography angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14173487" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : SPONTANEOUS CALCIFIC EMBOLIZATION ASSOCIATED WITH CALCIFIC AORTIC STENOSIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8623104" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Risk of stroke in a cohort of 815 patients with calcification of the aortic valve with or without stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254219" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Mitral annular calcification, aortic valve sclerosis, and incident stroke in adults free of clinical cardiovascular disease: the Strong Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574274" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15944423" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20048204" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18765433" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315272" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
